Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023
Telesis Bio (Nasdaq: TBIO) announced the release date for its fourth quarter and full year 2022 financial results, set for March 21, 2023, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Telesis Bio (Nasdaq: TBIO) announced the release date for its fourth quarter and full year 2022 financial results, set for March 21, 2023, after market close. Management will host a conference call at 1:30 p.m. PT to discuss the results and corporate highlights. The event is accessible via the Investor section of their website. Telesis Bio specializes in automated multi-omic and synthetic biology solutions, providing technologies like Gibson Assembly and the BioXp system, aimed at enhancing synthetic biology workflows for advancements in precision medicine, vaccine development, and genome editing.
Positive
- Upcoming financial results announcement on March 21, 2023, may provide investors with updated performance metrics.
- Telesis Bio is a leader in automated synthetic biology, enhancing its position in high-value markets like precision medicine and therapeutics.
Negative
- None.
Details
News Market Reaction – TBIO
The recorded move for TBIO in the trading session of this news was -5.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, March 21, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of Telesis Bio’s website at https://ir.telesisbio.com/. The conference call can be accessed by registering at this link: https://register.vevent.com/register/BI9516570548a545e393b0e9afc0337545. Please log in approximately 5 to 10 minutes before the event to ensure a timely connection. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. A replay of the conference call webcast will be available shortly after the live event and archived on the Investors section of the Telesis Bio website for at least 30 days.
About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.
Contact:
Jen Carroll
Vice President of Investor Relations
jen.carroll@telesisbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.